Business Context and Reporting Period
This Form 8-K was filed by Revelation Biosciences, Inc. on December 12, 2022, reporting events occurring on December 6, 2022. The Company is a Delaware corporation with principal executive offices in San Diego, California. Its securities, including Units (REVBU), Common Stock (REVB), and Redeemable Warrants (REVBW), are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing status rather than financial performance metrics.
Material Changes
The primary material event is the Company's failure to maintain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Key developments include:
- On December 6, 2022, the Company received notice from Nasdaq that it was not in compliance with the minimum bid price requirement.
- The Company had previously been granted a 180-day grace period to regain compliance, which expired on December 5, 2022.
- Following the expiration of the grace period, Nasdaq Staff issued a notice stating the bid price issue provides a separate basis for delisting.
- The Company has requested a hearing with the Nasdaq Hearings Panel to present a plan for regaining compliance.
Outlook, Risks, and Management Commentary
Management intends to take all reasonable measures to regain compliance with Nasdaq Listing Rules and remain listed. However, the filing explicitly states there can be no assurance that the Panel will grant an extension or that the Company will ultimately regain compliance. The Company notes that its noncompliance does not have an immediate effect on the listing or trading of its securities, which will continue to trade on The Nasdaq Capital Market pending the outcome of the hearing process.
Investor Verification Checklist
- Verify the current trading price of REVB to assess the severity of the bid price deficiency.
- Monitor the status of the hearing request with the Nasdaq Hearings Panel and any subsequent rulings.
- Review the Company's specific plan for regaining compliance, which is to be presented to the Panel.
- Check for any future 8-K filings regarding the final determination of the delisting risk.